Hims & Hers acquired Montreal-based Livewell in December 2025 to position itself for the Canadian generic semaglutide market. If you were a Livewell patient, your account has transitioned to the Hims & Hers platform at forhers.ca. The company plans to offer generic semaglutide once Health Canada approves it, potentially at lower prices than current competitors.
If you search "livewell ozempic" right now, you will land on a redirect page. That is because Livewell, the Canadian telehealth platform many patients used for weight loss prescriptions, no longer exists as a standalone company. Hims & Hers Health acquired it in late 2025, and the transition has left a lot of Canadian patients with questions.
I want to walk through what happened, what it means for existing patients, and whether Hims Canada will actually deliver on its promises around cheaper semaglutide.
What Was Livewell Health Canada?
Livewell was a Montreal-based digital health platform that focused on weight loss treatment. Founded by Antoine Arbour and Patrick Duffy, the company connected Canadian patients with licensed healthcare providers through a telehealth model. Patients could consult with a doctor online, get a prescription for weight loss medication (including Ozempic), and have it shipped to their door.
Livewell operated across multiple Canadian provinces and built a loyal user base by making the prescription process faster than the traditional walk-in-clinic route. Their Trustpilot page (still active under joinlivewell.ca) shows reviews from patients across BC, Ontario, Manitoba, and other provinces.
The company was not huge by US telehealth standards, but in Canada's smaller market, it carved out a real niche among patients who wanted a straightforward path to GLP-1 medications without multi-week wait times.
Why Did Hims & Hers Acquire Livewell?
The timing tells the story. Hims & Hers announced the Livewell acquisition on December 4, 2025, exactly one month before Novo Nordisk's data exclusivity on semaglutide expired in Canada on January 4, 2026.
Andrew Dudum, the co-founder and CEO of Hims & Hers, was blunt about the strategy. The company sees a massive opportunity: almost two-thirds of Canadian adults are overweight or living with obesity, but current branded semaglutide prices (over $200 per month without insurance) put treatment out of reach for many.
By acquiring Livewell, Hims & Hers got three things it could not build from scratch fast enough: Canadian medical licenses and regulatory infrastructure, an existing patient base, and a local leadership team. Antoine Arbour and Patrick Duffy (Livewell's co-founders) joined the Hims & Hers Canadian leadership team, alongside newly appointed General Manager Austin Kouri and Chief Medical Officer Dr. Sandy Van, MD, CCFP, ABOM Dipl.
For context, Hims & Hers is not a small startup. The company has been on a $1.8 billion revenue trajectory in the US, where it offers everything from hair loss treatments to mental health prescriptions through its telehealth platform. Canada is its second international market after the UK (where it acquired ZAVA).
What Changes for Existing Livewell Patients
If you were a Livewell customer, here is what has changed:
Your account has moved. Livewell's website (joinlivewell.ca) now redirects to forhers.ca, the Canadian arm of Hims & Hers. Your patient profile and prescription history should have transferred over.
Your prescriptions remain valid. Any active prescription you had through Livewell is still valid. The prescribing physician network has carried over under the Hims & Hers medical team, now led by Dr. Sandy Van.
Pricing may have changed. Some patient reviews on Trustpilot mention pricing differences after the transition. If your costs changed, contact their support team directly to ask about current program fees.
The platform looks different. Livewell's simple interface has been replaced by the Hims & Hers platform, which has more features but can feel busier. The core service is the same: online consultation, prescription, pharmacy delivery.
No interruption in medication access. According to the company's official statements, there should be no gap in service for existing patients during the transition.
If you are having trouble logging in or accessing your account, try forhers.ca first. If that does not work, reach out to their customer support. During acquisition transitions, some accounts take a few weeks to fully migrate.
What Hims Canada Will Offer — The Generic Semaglutide Plan
This is where things get interesting. Hims & Hers has been public about its plan to offer generic semaglutide in Canada as soon as Health Canada approves it.
They will offer generic semaglutide through the platform. The company has stated this directly in press releases and investor communications. Their weight loss program in Canada is designed around generic semaglutide as the core medication.
They are targeting lower pricing. In the US, Hims & Hers built a reputation for offering treatments at lower prices than traditional pharmacies. In Canada, they have said that branded semaglutide without clinical guidance costs over $200 per month, and they intend to offer generic versions at a lower cost. Exact Canadian pricing has not been announced.
Timeline depends on Health Canada. Like everyone else, Hims Canada is waiting for Health Canada to approve generic semaglutide applications. The most realistic timeline is summer to early fall 2026 based on expert estimates.
They have a generic semaglutide waitlist. You can sign up at forhers.ca/generic-semaglutide-waitlist to be notified when generic options become available through their platform.
What Should Canadian Patients Do Right Now?
If you are a former Livewell patient: Log into forhers.ca and check that your account, prescription history, and any active prescriptions transferred correctly. If anything looks off, contact support.
If you are considering semaglutide for the first time: Do not wait for Hims Canada if you need treatment now. Felix Health and Maple are both operating and can connect you with a physician within 24 to 48 hours.
If cost is your main barrier: Consider waiting for generic semaglutide, expected by summer/fall 2026. Prices should drop from $250-$570 per month to roughly $100 to $150. Sign up for waitlists at both Felix and Hims to get notified.
If you are currently stable on branded Ozempic or Wegovy: No need to change anything right now. Your medication, dose, and prescription will remain the same regardless of which telehealth company you use or whether generics launch. Talk to your provider before switching to a generic version when one becomes available.
Frequently Asked Questions
Is Hims available in Canada now?
Partially. Hims & Hers officially entered the Canadian market in December 2025 through the Livewell acquisition. The company is operational at forhers.ca, but its full weight loss program with generic semaglutide has not launched yet.
Will Hims Canada offer generic semaglutide?
Yes. Hims & Hers has publicly stated that offering generic semaglutide in Canada is central to their expansion plan. The timing depends on Health Canada's approval of generic semaglutide applications, expected by summer or fall 2026.
What happened to my Livewell subscription?
Livewell has been absorbed into Hims & Hers. Your account should have migrated to forhers.ca. If you had an active prescription, it should still be valid. Contact the support team at forhers.ca if you cannot access your account.
Is Hims Canada cheaper than Felix?
Not yet clear. Hims Canada has not announced specific pricing for its weight loss program. Felix currently charges a $99 initial fee plus $40 quarterly checkups, plus medication costs starting at $312 per pen.
When will Hims Canada fully launch?
The company has said it plans to expand its Canadian weight loss program in 2026, timed to generic semaglutide availability. A full launch with generic options likely depends on Health Canada approving at least one generic manufacturer, expected Q3 2026.
This article is for informational purposes only and does not constitute medical advice. Always consult a licensed Canadian healthcare provider before starting, stopping or changing any medication.